Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients

Intensive care unit (ICU) admissions and mortality in severe COVID-19 patients are driven by “cytokine storms” and acute respiratory distress syndrome (ARDS). Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requ...

Descripción completa

Detalles Bibliográficos
Autores principales: Awasthi, Samir, Wagner, Tyler, Venkatakrishnan, A. J., Puranik, Arjun, Hurchik, Matthew, Agarwal, Vineet, Conrad, Ian, Kirkup, Christian, Arunachalam, Raman, O’Horo, John, Kremers, Walter, Kashyap, Rahul, Morice, William, Halamka, John, Williams, Amy W., Faubion, William A., Badley, Andrew D., Gores, Gregory J., Soundararajan, Venky
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958587/
https://www.ncbi.nlm.nih.gov/pubmed/33723251
http://dx.doi.org/10.1038/s41420-021-00429-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958587/
https://www.ncbi.nlm.nih.gov/pubmed/33723251
http://dx.doi.org/10.1038/s41420-021-00429-9

Ejemplares similares